Clinical trial
A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult…
NCT00056836 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00056836 |
|---|---|
| Title | A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration |
| Official title | A Phase III, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects With Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Macular Degeneration |
| Intervention type | Drug |
| Interventions | rhuFab V2 (ranibizumab) |
| Enrollment | 720 |
| Start date | Mar 1, 2003 |
| Completion | Dec 1, 2005 |
| First posted | Mar 26, 2003 |
| Last update posted | May 16, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: